Common Blood Pressure Medication Shows Promise in Slowing Aggressive Cancers

Recent research reveals that hydralazine, a longtime blood pressure medication, may hold potential for fighting aggressive forms of cancer. Initially used since the 1950s to manage hypertension, scientists unexpectedly discovered its ability to impact cancer progression.

Kyosuke Shishikura, a physician-scientist at the University of Pennsylvania, explained that hydralazine originated from an era of drug discovery focused more on patient observation than on clear biological understanding. This shift in focus now offers new insights into cancer treatment possibilities.

Understanding Hydralazine’s Mechanism

In this groundbreaking study, Shishikura and his research team identified a critical target of hydralazine: a small enzyme known as 2-aminoethanethiol dioxygenase, or ADO. This enzyme plays a crucial role as a cellular oxygen sensor, vital for cell survival in low-oxygen environments.

Fast-growing tumors, particularly glioblastoma, can exploit this mechanism. Glioblastoma is a notably aggressive brain cancer that is highly resistant to treatment and has a tendency to recur. Due to the rapid proliferation of tumor cells, their blood supply often lags, creating areas of hypoxia or low oxygen.

The Survival Strategies of Tumor Cells

While normal cells typically perish in low-oxygen scenarios, tumor cells employ special survival strategies. These systems enable malignant cells to continue growing despite oxygen scarcity. Among these strategies is the function of the ADO enzyme, which helps cancer cells thrive when conditions are challenging.

Megan Matthews, an assistant professor in the Department of Chemistry at Penn, elaborated on the enzyme’s role. She referred to ADO as an alarm bell that triggers when oxygen levels begin to decline. By obstructing ADO’s functionality, hydralazine can effectively silence this alarm, impeding cancer cell survival.

Investigating Hydralazine’s Impact on Cancer Cells

The research team utilized advanced techniques like X-ray crystallography to examine how hydralazine interacts with ADO. Their findings demonstrated that hydralazine effectively inhibits the enzyme, thus deactivating the cell’s oxygen response system. This action has the potential to halt the relentless division of cancer cells.

In laboratory tests involving human glioblastoma cells, researchers observed remarkable results after a three-day treatment period. The treated cells ceased to proliferate, undergoing a transformation into a state known as senescence, where they become larger and flatter. This discovery indicates a significant step toward controlling glioblastoma growth.

Implications for Future Cancer Treatments

While hydralazine does not kill the cancer cells outright, it significantly diminishes their capacity to grow and metastasize. This represents a crucial advancement in managing glioblastoma, particularly due to the challenges of treating these tumors effectively after initial therapies such as surgery and chemotherapy.

Since hydralazine has already received FDA approval, researchers are optimistic about its potential to be repurposed for cancer therapy more swiftly than the introduction of a completely new drug. This expediency could prove vital in the fight against aggressive cancers.

Next Steps for Research

It is important to note that all experiments conducted thus far have only involved cell cultures, as hydralazine has not yet been tested in live animal or human subjects. The research team plans to explore whether ADO can be inhibited safely and effectively in living systems.

The preliminary nature of this discovery signals that while the findings are promising, they remain far from clinical application. The researchers emphasize that understanding how hydralazine operates at a molecular level provides a potential path toward developing safer and more targeted cancer treatments.

Looking Ahead: A New Hope in Cancer Treatment

As the research progresses, scientists remain encouraged by the potential of hydralazine in oncology. Shishikura and Matthews both express a commitment to further exploring the mechanisms at play, with the ultimate goal of transforming this blood pressure medication into a viable option for cancer patients. The potential for repurposing existing medications such as hydralazine could significantly change how aggressive cancers are treated in the future.

Ongoing studies and testing will be critical in determining whether hydralazine can indeed make a substantial impact on patient outcomes in cancer treatment.